<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3307">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02081001</url>
  </required_header>
  <id_info>
    <org_study_id>XSGO-201</org_study_id>
    <secondary_id>4R44DK096706-02</secondary_id>
    <nct_id>NCT02081001</nct_id>
  </id_info>
  <brief_title>PK/PD Study With G-Pump (Glucagon Infusion) in DM1 Patients</brief_title>
  <official_title>COMPARISON OF PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES OF G-PUMP™ (GLUCAGON INFUSION) VS GLUCAGEN® DELIVERED SUBCUTANEOUSLY TO SUBJECTS WITH TYPE 1 DIABETES (DM1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emissary International LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety, speed of absorption, and onset of action
      of G-Pump™ (glucagon infusion) at three doses as compared to Novo GlucaGen®, all delivered
      via an OmniPod® pump to patients with type 1 diabetes (DM1).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of G-Pump™ (glucagon infusion)</measure>
    <time_frame>From first dose until follow-up visit, an expected average time period of 3 weeks per subject.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety-related parameters include: Vital signs, physical exam, EKG, standard safety laboratory parameters and incidence of adverse events (AEs) as well as serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of G-Pump™ (glucagon infusion)</measure>
    <time_frame>Approximately 15 minutes before each injection until 3 hours post-injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>The onset of action will be assessed by the time to reach 50% of the maximum glucose concentration (TGLUCOSE-50%-early) and the speed of absorption will be assessed by the time to reach 50% of maximum glucagon concentration (TGLUCAGON-50%-early)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics:</measure>
    <time_frame>Approximately 15 minutes before each injection until 3 hours post-injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic parameters include:  AUCGLUCAGON 0-60, AUCGLUCAGON 0-120, AUCGLUCAGON 0-150, CGLUCAGON max, TGLUCAGON max, TGLUCAGON-50%-late</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic:</measure>
    <time_frame>Approximately 15 minutes before each injection until 3 hours post-injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUCGLUCOSE 0-60, AUCGLUCOSE 0-120, AUCGLUCOSE 0-150, Glumax, TGLUCOSE max, TGLUCOSE-50%-late</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Tolerability</measure>
    <time_frame>From 10 minutes post-injection until 3 hours post-injection</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Infusion site discomfort as assessed using a 100 mm Visual Analog Scale (VAS) Infusion site discomfort assessed using a categorical (ordinal) infusion site discomfort verbal rating scale Erythema and or edema formation at site of infusion assessed using the Draize scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>G-Pump™ (glucagon infusion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-Pump™ (glucagon infusion); single subcutaneous infusion of each of 0.3 μg/kg, 1.2 μg/kg, and 2.0 μg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Novo Nordisk GlucaGen®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Novo Nordisk GlucaGen®; single subcutaneous infusion of each of 0.3 μg/kg, 1.2 μg/kg, and 2.0 μg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novo Nordisk GlucaGen®</intervention_name>
    <description>single subcutaneous infusion of each of 0.3 μg/kg, 1.2 μg/kg, and 2.0 μg/kg</description>
    <arm_group_label>G-Pump™ (glucagon infusion)</arm_group_label>
    <arm_group_label>Novo Nordisk GlucaGen®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-Pump™ (glucagon infusion)</intervention_name>
    <description>single subcutaneous infusion of each of 0.3 μg/kg, 1.2 μg/kg, and 2.0 μg/kg</description>
    <arm_group_label>G-Pump™ (glucagon infusion)</arm_group_label>
    <arm_group_label>Novo Nordisk GlucaGen®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females diagnosed with type 1 diabetes mellitus for at least 24 months

          -  Current usage of subcutaneous insulin pump treatment

          -  Age 18-65 years

          -  C-peptide level &lt; 0.5 ng/ml

          -  Willingness to follow all study procedures, including attending all clinic visits

          -  Subject has provided informed consent and has signed and dated an informed consent
             form before any trial-related activities

        Exclusion Criteria:

          -  Pregnant and/ or Lactating: For women of childbearing potential: there is a
             requirement for a negative urine pregnancy test and for agreement to use
             contraception during the study and for at least 1 month after participating in the
             study.

          -  HbA1c &gt;9.0%

          -  Renal insufficiency (serum creatinine of 1.2 mg/dL or greater)

          -  Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic
             synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL; or serum
             bilirubin of over 2.0.

          -  Hematocrit of less than or equal to 34%

          -  Congestive heart failure, NYHA class II, III or IV

          -  History of Coronary artery disease

          -  Active foot ulceration

          -  History of a cerebrovascular accident

          -  Active alcohol abuse or substance abuse

          -  Active malignancy, except basal cell or squamous cell skin cancers

          -  Major surgical operation within 30 days prior to screening

          -  Seizure disorder

          -  Current administration of oral or parenteral corticosteroids

          -  Use of an investigational drug within 30 days prior to screening

          -  Bleeding disorder, treatment with warfarin, or platelet count below 50,000

          -  Proliferative or severe non-proliferative retinopathy

          -  Gastroparesis

          -  Personal or family history of pheochromocytoma or disorder with increased risk of
             pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease)

          -  Insulinoma

          -  Allergies to glucagon or glucagon-like products, or any history of significant
             hypersensitivity to glucagon or any related products.

          -  Glycogen storage disease

          -  Any concurrent illness, other than diabetes, that is not controlled by a stable
             therapeutic regimen

          -  Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening.

          -  Any reason the principal investigator deems exclusionary
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Castle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Branigan</last_name>
      <phone>503-418-9070</phone>
      <email>branigad@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica Castle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 7, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoglycemia</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Artificial Pancreas</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
